Web Stats Provided By Google Analytics

The Raw Stem Cell News Feed

The Stem Cell Research Newswire: Comprehensive Real-Time News Feed for Stem Cell Research

Tuesday, April 21, 2015

BrainStorm's NurOwn Demonstrates a Statistically Significant Effect in ALS Patients

BrainStorm Cell Therapeutics Inc. , a leading developer of adult stem cell technologies for neurodegenerative diseases, is presenting results from its phase 2a study of NurOwn in amyotrophic lateral sclerosis at a poster session today at the American Academy of Neurology annual meeting, taking place in Washington D.C. In addition to previously disclosed topline results, further data and analyses are being presented for the first time today. Among the new results is a piecewise linear regression analysis of all subjects who received intrathecal administration in the phase 2a study and the prior phase 1/2 study.

No comments:

Post a Comment

Popular Stem Cell Roundup Posts